Dengue Vaccine TAK-003 Cleared by DCGI

Recently, Takeda’s dengue vaccine TAK-003 (Qdenga) received clearance from the Subject Expert Committee under the Drugs Controller General of India (DCGI) for use in individuals aged 4-60 years.

  • This marks a major milestone in India’s fight against dengue, which causes millions of infections and thousands of hospitalisations annually.
  • It has been tested on over 28,000 participants and approved in 40+ countries.
  • The vaccine provides strong protection against severe dengue and hospitalisation.
  • It does not require pre-vaccination screening, making it easier to deploy in public health programmes.
  • However, its effectiveness varies across serotypes, with relatively lower protection against DENV-3 and DENV-4.
  • The vaccine ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Science & Technology